-
公开(公告)号:EP2872514A1
公开(公告)日:2015-05-20
申请号:EP13739922.6
申请日:2013-07-12
发明人: PURANDARE, Ashok Vinayak , FINK, Brian E. , JOHNSON, Walter Lewis , HART, Amy C. , HE, Liqi , HUYNH, Tram N. , INGHRIM, Jennifer , MASTALERZ, Harold , SANG, Xiaopeng , TARBY, Christine M. , WAN, Honghe , VACCARO, Wayne , ZHANG, Guifen , ZHAO, Yufen , ZIMMERMANN, Kurt , ZHANG, Yong , CHEN, Libing , CHEN, Bin , TOKARSKI, John S. , GAVAI, Ashvinikumar V.
IPC分类号: C07D487/04 , A61K31/53 , A61P17/08 , A61P19/02 , A61P35/00
CPC分类号: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/65213 , C07F9/6561 , C07F9/65616
摘要: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.
摘要翻译: 本发明提供式(I)的化合物及其药学上可接受的盐。 式(I)咪唑并三嗪抑制蛋白激酶活性,从而使它们可用作抗癌剂。
-
公开(公告)号:EP2872514B1
公开(公告)日:2017-08-30
申请号:EP13739922.6
申请日:2013-07-12
发明人: PURANDARE, Ashok Vinayak , FINK, Brian E. , JOHNSON, Walter Lewis , HART, Amy C. , HE, Liqi , HUYNH, Tram N. , INGHRIM, Jennifer , MASTALERZ, Harold , SANG, Xiaopeng , TARBY, Christine M. , WAN, Honghe , VACCARO, Wayne , ZHANG, Guifen , ZHAO, Yufen , ZIMMERMANN, Kurt , ZHANG, Yong , CHEN, Libing , CHEN, Bin , TOKARSKI, John S. , GAVAI, Ashvinikumar V.
IPC分类号: C07D487/04 , A61K31/53 , A61P17/08 , A61P19/02 , A61P35/00
CPC分类号: C07D487/04 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K31/541 , A61K31/55 , A61K31/551 , A61K31/675 , A61K45/06 , C07D471/10 , C07D487/08 , C07D487/10 , C07D487/22 , C07D498/04 , C07D519/00 , C07F7/1804 , C07F9/65213 , C07F9/6561 , C07F9/65616
-
公开(公告)号:EP2041138B1
公开(公告)日:2014-06-25
申请号:EP07799265.9
申请日:2007-07-03
发明人: MASTALERZ, Harold , WITTMAN, Mark D. , ZIMMERMANN, Kurt , SAULNIER, Mark G. , VELAPARTHI, Upender , VYAS, Dolatrai M. , ZHANG, Guifen , JOHNSON, Walter Lewis , FRENNESSON, David B. , SANG, Xiaopeng , LIU, Peiying , LANGLEY, David R.
IPC分类号: C07D487/04 , A61K31/53 , A61P35/00 , A61P25/00 , C07D519/00
CPC分类号: C07D487/04 , C07D519/00
-
公开(公告)号:EP2041138A2
公开(公告)日:2009-04-01
申请号:EP07799265.9
申请日:2007-07-03
发明人: MASTALERZ, Harold , WITTMAN, Mark D. , ZIMMERMANN, Kurt , SAULNIER, Mark G. , VELAPARTHI, Upender , VYAS, Dolatrai M. , ZHANG, Guifen , JOHNSON, Walter Lewis , FRENNESSON, David B. , SANG, Xiaopeng , LIU, Peiying , LANGLEY, David R.
IPC分类号: C07D487/04 , A61K31/53 , A61P35/00 , A61P25/00
CPC分类号: C07D487/04 , C07D519/00
摘要: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
摘要翻译: 本发明提供了式I化合物及其药学上可接受的盐。 式I化合物抑制酪氨酸激酶活性,从而使它们可用作抗癌剂并用于治疗阿尔茨海默氏病。
-
-
-